Oncolytic Virotherapy with the Fusogenic VSV-NDV Platform Complementing Adoptive T Cell Therapy
- Alternative title
-
Onkolytische Virotherapie mit der fusogenen VSV-NDV Platform komplementiert adoptive T-Zell-Therapie
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
München, Technische Universität München, Dissertation, 2020
- Event
-
Veröffentlichung
- (where)
-
München
- (who)
-
Universitätsbibliothek der TU München
- (when)
-
2020
- Creator
-
Krabbe, Teresa
- Contributor
-
Altomonte, Jennifer
Krackhardt, Angela
Kreppel, Florian
- URN
-
urn:nbn:de:bvb:91-diss-20200715-1544520-1-5
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Krabbe, Teresa
- Altomonte, Jennifer
- Krackhardt, Angela
- Kreppel, Florian
- Universitätsbibliothek der TU München
Time of origin
- 2020
Other Objects (12)
Oncolytic virotherapy of glioblastoma
Vesicular stomatitis virus (VSV)-based systems for oncolytic virotherapy of malignant glioma
Immune checkpoint modulation enhances oncolytic virotherapy
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Key parameters of measles virus production for oncolytic virotherapy
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Oncolytic virotherapy of glioblastoma
Vesicular stomatitis virus (VSV)-based systems for oncolytic virotherapy of malignant glioma
Immune checkpoint modulation enhances oncolytic virotherapy
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Key parameters of measles virus production for oncolytic virotherapy
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Oncolytic virotherapy of glioblastoma
Vesicular stomatitis virus (VSV)-based systems for oncolytic virotherapy of malignant glioma
Immune checkpoint modulation enhances oncolytic virotherapy
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Key parameters of measles virus production for oncolytic virotherapy
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies